ARS Pharmaceuticals, Inc. · Brief

Next report

8 days

Nov 9 · before openest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

1 of 8≥ implied

Jan 13 '25±9.4%▲+0.18%×0.02

Mar 20 '25±11.8%▲+22.83%×1.93

May 14 '25±11.9%▼−9.36%×0.79

Aug 13 '25±14.4%▼−5.04%×0.35

Q3 FY25±18.0%▲+0.34%×0.02

Q1 FY26±22.8%▼−0.11%×0.00

May 15 '26±11.3%▼−6.49%×0.58

Q2 FY26±22.2%▼−7.38%×0.33

quarterimplied−25%0+25%realized×

Q2 FY26±22.2%▼−7.38%×0.33

May '26±11.3%▼−6.49%×0.58

Q1 FY26±22.8%▼−0.11%×0.00

Q3 FY25±18.0%▲+0.34%×0.02

Aug '25±14.4%▼−5.04%×0.35

May '25±11.9%▼−9.36%×0.79

2 older reports

Mar '25±11.8%▲+22.83%×1.93

Jan '25±9.4%▲+0.18%×0.02

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 9 report · est.

Bull2 of 3

20disclosed supplier and customer ties in SEC filingsSEC filings

205managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 4

7 of 8recent reports where the move came in under the options implied rangeEarnings history

4 of 23of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

SPRY report session

No linked exposure.

Oct 26impliedImplied move: ±45.6% into Nov 9 earnings (Oct 26 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.